85,365 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Purchased by DnB Asset Management AS

DnB Asset Management AS purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 85,365 shares of the company's stock, valued at approximately $577,000.

A number of other large investors have also recently made changes to their positions in RXRX. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth $26,000. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth approximately $27,000. GAMMA Investing LLC raised its position in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after buying an additional 4,948 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 220.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock valued at $66,000 after purchasing an additional 6,758 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Down 11.9 %

RXRX traded down $0.57 during trading on Friday, reaching $4.24. 28,071,567 shares of the stock traded hands, compared to its average volume of 11,038,431. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $12.36. The stock's 50-day simple moving average is $7.22 and its two-hundred day simple moving average is $6.95. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -2.77 and a beta of 1.00.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period in the prior year, the firm earned ($0.42) EPS. Recursion Pharmaceuticals's quarterly revenue was down 57.8% on a year-over-year basis. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of research reports. Needham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.